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Ion mobilityMonoclonal antibodies (mAbs) are powerful therapeutics, and their characterization has drawn con-
siderable attention and urgency. Unlike small-molecule drugs (150–600 Da) that have rigid struc-
tures, mAbs (150 kDa) are engineered proteins that undergo complicated folding and can exist
in a number of low-energy structures, posing a challenge for traditional methods in structural biol-
ogy. Mass spectrometry (MS)-based biophysical characterization approaches can provide structural
information, bringing high sensitivity, fast turnaround, and small sample consumption. This review
outlines various MS-based strategies for protein biophysical characterization and then reviews how
these strategies provide structural information of mAbs at the protein level (intact or top-down
approaches), peptide, and residue level (bottom-up approaches), affording information on higher
order structure, aggregation, and the nature of antibody complexes.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Therapeutic monoclonal antibodies (mAbs) to identify and neutralize foreign organisms or antigens [4,5]. Ig’sTherapeuticmAbsmay have become themost popular drug can-
didates following their introduction into the clinic in the late 1980s
[1]. Their high speciﬁcity and low side effects make mAbs powerful
human therapeutics for oncology, autoimmunity/inﬂammation,
infectious diseases, andmetabolic disorders [2]. At present, approx-
imately 30 therapeuticmAbs are beingmarketed. The sales contrib-
uted approximately $18.5 billion to the US economy in 2010 [1].
The high demands for new therapeutic mAbs have trigged a burst
of mAb-based drug development. For example, 16 humanmAbs en-
tered the clinic during 1985–1996, whereas during 1997–2008, 131
human mAbs became available [3]. In 2011, more than 300
mAb-based thereapeutics were in clinical trials [2]. As older mAbs
come off patent and go into production as generic drugs, the need
for characterizing their higher order structure in quality control be-
comes even more important, motivating this review.
1.1. Introduction to mAbs
Therapeutic mAbs are glycoproteins that belong to the
immunoglobulin (Ig) family. Ig’s are used by the immune systemare classiﬁed in ﬁve groups, IgA, IgD, IgE, IgG and IgM (as a, d, e, c
and l), based on the structure of their constant regions [6]. At pres-
ent, most approved mAbs are from IgG’s (c-immunoglobulin). IgG’s
have the typical ‘‘Y’’-shaped structure comprised of two identical
heavy and light chains (H and L chains) (Fig. 1). All heavy and light
chains are covalently linked by disulﬁde bonds. IgGs can be further
classiﬁed into four groups, IgG1, 2, 3, and IgG4 (as c-1, c-2, c-3 and
c-4) on the basis of different patterns of inter-chain disulﬁde bonds
and heavy-chain sequences. IgG1, 2 and 4 are widely used in ther-
apeutics, whereas IgG3, which has a shorter serum half-life, is
rarely used.
Each heavy chain contains one variable (VH) and three constant
domains (CH1, CH2 and CH3), whereas each light chain contains
one variable (VL) and one constant domain (CL). In the heavy chain,
CH1 and CH2 are linked by a hinge region that contains inter-heavy
chain disulﬁde bonds (IgG1 and IgG4 have two disulﬁde bonds in
hinge region, whereas IgG2 has four). Antigen binding is mediated
by the variable region, mainly by three loops connecting individual
b-strands, which are called the complementarity determining re-
gions (CDRs), from both heavy and light chains. Upstream of the
heavy chain (VH and CH1) is the disulﬁde-bond-linked light chain
(VL and CL), known as the fragment antigen-binding (Fab) region.
The downstream constant regions (CH2 and CH3) of the heavy
Fig. 1. IgG structure (IgG1). The global structure of IgG1 has two identical heavy
chains and light chains. Four chains are attached covalently with inter-chain
disulﬁde bonds and also by non-covalent interactions. The two constant regions
from heavy chains (CH2 and CH3, Fc regions) respond to the binding to Fc gamma
and FcRn receptors. The variable region from both light and heavy chains contains
antigen-binding regions (CDRs). Variable regions with the close constant region
together are called the Fab region. The Fab and Fc region are linked by the hinge
region in the heavy chain. In the IgG1, there is a glycosylation site on the second
constant region (CH2).
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responsible for effector function during recycling [7].
A milestone in the development of therapeutic engineered
mAbs was the introduction of murine mAbs from hybridomas
[8]. Clinical applications of murine mAbs (sufﬁx: -omab) began in
the late 1980s [9]. Dissimilarities between murine and human im-
mune systems led to clinical failure of those antibodies. Murine
antibodies are engineered to generate chimeric mouse-human
mAbs (65% human in molecules, sufﬁx: -ximab) by fusing the
murine-variable regions onto human-constant regions [10]. The
humanized mAbs (95% human in molecules, sufﬁx: -zumab) are
produced by grafting murine hyper-variable regions on amino acid
domains of human antibodies [11]. Both chimeric mouse-human
and humanizedmAbs have reduced immunogenicity and increased
serum half-life [12]. With the development of phage-display tech-
nology and various transgenic mouse strains expressing human
variable domains [13,14], fully human mAbs (sufﬁx: -umab) with
signiﬁcantly reduced immunogenic potential and high similarity
to human endogenous IgGs, have become rich sources of new ther-
apeutics [1,3,15].
1.2. The challenge of verifying higher order structure of therapeutic
mAbs
Unlike traditional small molecular drugs (150–600 Da), mAbs
are large macromolecules (150 kDa) with four polypeptide chains
held in place by tens of inter- or intra-disulﬁde bonds as well as by
non-covalent interactions [6]. For example, one approved thera-
peutic mAb, trastuzumab, has 6560 carbon atoms, 10132 hydro-
gens, 2090 oxygens, 1728 nitrogens and 44 sulfur atoms [16].
The functional form of the protein depends on its higher order
structure (HOS), referring to the tertiary 3-D architecture deter-
mined by the secondary alpha-helices and beta-sheets, building
upon the primary structure, and the quaternary complex formed
by interacting/binding with other entities. Sources affecting the
HOS of mAbs are not limited to primary structures. Variations in
PTMs (post-translational modiﬁcations), mutations and modiﬁca-
tions can trigger changes in HOS to affect binding to an antigen
or to Fc-gamma and Fc-Rn receptors. Production and storage of
therapeutic mAbs can introduce signiﬁcant changes of HOS. Fromthe view of patient health, HOS variations of these proteins can
pose serious safety issues [17,18]. HOS can be ﬂeeting for proteins;
HOS is certainly more dynamic than primary structure. Although
strategies to determine the primary structure of mAbs, including
mutations, PTMs, and other modiﬁcations, have been available
for decades, approaches to verify HOS are still needed. Although
circular dichroism (CD), ﬂuorescence and related optical spectro-
scopic methods are used for rapid HOS characterization [19], many
regional but important structural changes are missed [20]. In the
recently published draft guidelines for quality control of biosimi-
lars (copies of therapeutic mAbs that are coming off patent), the
US Food and Drug Administration (FDA) acknowledged that ‘‘a
protein’s three-dimensional conformation can often be difﬁcult to
deﬁne precisely using current physicochemical analytical technol-
ogy’’. New approaches are under development to meet this chal-
lenge [16,20]. In this review, we focus on the new and promising
MS-based biophysical approaches as means for characterization
of mAb HOS.
2. Mass spectrometry based protein biophysics
2.1. Overview
The advantages of MS in biology are attracting the attention of
structural biologists who address the biophysical properties of pro-
teins [21]. Modern MS instrumentation and proteomics methods
offer two major approaches to interrogate protein biophysics.
One is an intact or top-down approach that employs native electro-
spray ionization (ESI), ion-mobility measurements, and fragmenta-
tion, usually by interaction with electrons, to provide a global view
of the protein of interest [22]. The other is a bottom-up approach
combining either protein footprinting [23] or cross-linking [24]
that provide detailed peptide and even amino-acid-residue infor-
mation. These terms ‘‘top down’’ and ‘‘bottom-up’’ ﬁrst appeared
in the MS-based proteomics literature [25]. Compared to bottom-
up, top-down is less mature, requiring the invention of electron
capture dissociation (ECD) [26] in 1998. Both top-down and bot-
tom-up MS approaches have the advantages of small sample con-
sumption, nearly no limit to protein size, and ability to determine
in the gas phase the native or near-native protein properties. Fur-
thermore, MS can be combined with protein footprinting to give an
approach that is tolerant to solution media containing MS-
unfriendly small molecules. Native ESI and top-down sequencing
offer high throughput and unique speciﬁcity for oligomeric states
and stoichiometry of native protein samples. By combining these
complementary MS methods, important structural information
can be discovered with intermediate structural resolution. We will
review the principles of both approaches in the following
subsections.
2.2. Intact and top-down based approach
At present, proteins and protein complexes with MW even at
the mega-Dalton range can be directly analyzed by MS [27]. Top-
down protocols provide information without requiring proteolytic
digestion of protein samples prior to MS analysis [28]. Removing
the digestion step should signiﬁcantly reduce analysis time. Intact
proteins and protein complexes are then interrogated close to their
functional forms, even as protein assemblies [29]. Species existing
in different oligomeric states or with PTMs can be analyzed sepa-
rately. Although targeted analysis (e.g., oligomer speciﬁc analysis)
can also be accomplished by bottom-up approaches by adding a
pre-separation step, top-down approaches are more efﬁcient.
Using an approach targeting intact proteins, we can directly
monitor the charge-state distribution and obtain stoichiometry
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and capture some information about shape and changes in shape
by keeping the protein in near-native states in the gas phase.
Tandem MS capabilities available on most commercial MS instru-
ments can also be employed to elucidate the conformations by
fragmenting portions of a protein or protein complex and inter-
preting the decomposition reactions. An overview of top-down
MS strategies is summarized in Fig. 2A where native ESI in the
upper half preserves the protein structure; while normal ESI in
the lower half deals with proteins that are denatured, and such
proteins can be studied further by limited or speciﬁc proteolysis
to generate large peptide fragments (middle-out) to improve the
sequence coverage by MS/MS in a way of middle-down/up that is
similar to bottom-up approach but for large peptides.
2.2.1. Native MS (or native ESI)
Native MS has proved to be an alternative strategy to
investigate structure in the near-native state of intact proteins
and their complexes by using MS platforms that work for
gas-phase species [22]. Prior to conducting an MS experiment,
the original buffer solution that maintains the protein’s native
structure is exchanged with a volatile ammonium acetate solution
that mimics the native buffer but favors solvent (and salt) evapora-
tion during ESI to release protein ions that bear a memory of their
structure in solution [30]. In this way, the ionized proteins carry
less charge (are less protonated on the surface) than those gener-
ated by normal ESI, which utilizes denaturing solutions comprised
of water and organic solvents at low pH. As a result, the ions seen
in the mass spectrum produced by a native ESI experiment appear
at higher m/z.
The non-covalent interactions within a protein and between
subunits of protein assemblies can also be preserved in the gas
phase [29]. It is sometimes relatively straightforward to deter-
mine the stoichiometry of a complex by using native MS. More
importantly, variations within proteins or protein complexes
can be monitored based on their charge-state distribution in na-
tive MS [31]. Highly ordered or compact proteins and protein
complexes have smaller surface areas than disordered or unfolded
ones. This difference can be directly read out from the charge-
state distribution [32]. Following the introduction of protein ions
into the gas phase, they can be interrogated by ion mobility or
tandem MS to obtain structural information, all in a top-down
manner [33,34].Fig. 2. Overview of top-down and bottom-up MS based protein biophysical studies (usin
right circle is the summary of bottom-up approaches.2.2.2. Ion mobility measurements
Gas-phase ion mobility provides a collisional cross-section
(CCS) of a particular ion drifting through in inert buffer gas in a
low electrical ﬁeld [35]. In the drift region, an ion experiences
many collisions with inert buffer gas molecules. The upshot of this
ion drift is a two-dimension projection (or CCS) of the three-
dimension shape of the ion in free rotation. The readout is the time
for the ion to pass through the drift region (called an arrival time
distribution (ATD) or drift time). Ions with a large cross section
drift more slowly, affording an outcome that is similar to that of
a native-gel experiment. Thus, proteins and protein complexes
can be separated based on the difference of their native states.
An important application of ion mobility is to provide experimen-
tal evidence on native protein conformation, which appears to be
preserved, at least in part, in the gas phase when the protein is
introduced by native MS [36]. Mobility can be applied to differen-
tiate the structure of two ions of the same m/z, thus providing
information on shape and size in the gas phase [37]. Robinson
and coworkers [38,39] have used native ESI and ion mobility to
establish a calibration curve for the CCS of proteins and protein
complexes. Furthermore, these approaches have also facilitated
the investigation of large membrane-embedded protein complexes
[40].
2.2.3. Top-down fragmentation
MS/MS-based fragmentation of protein ions affords information
on primary structure. A number of approaches can be used to acti-
vate ions: collisionally activated dissociation (CAD), sometimes
called collision-induced dissociation (CID) [41], electron-capture
dissociation (ECD) [26], electron-transfer dissociation (ETD) [42],
surface-induced [43] dissociation, and photon-induced dissocia-
tion [44]. Top-down fragmentation in this context provides struc-
tural connectivity and compositions of the protein or protein
assembly [34]. As exempliﬁed by its applications in proteomics
[45], top-down sequencing overcomes a disadvantage of bottom-
up in which the digestion of the starting proteins leads to a loss
of information about protein isoforms, especially for PTMs.
Thus far, CAD/CID in a quadruple/time-of-ﬂight (TOF) instru-
ment has played the dominant role in characterization of native
protein complexes; it reveals the stoichiometry and topology of a
protein assembly [46]. Electron-capture dissociation (ECD) in a
Fourier transform ion cyclotron resonance (FTICR) mass spectrom-
eter can identify ﬂexible regions of a protein [47] to revealg antibody as example). The left circle is the summary of top-down approaches. The
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Surface-induced dissociation (SID) tends to release and to distrib-
ute charges symmetrically among the fragmented subcomplexes
[49].
2.3. Bottom-up approaches
In bottom-up approaches, proteins are digested into peptides
before MS analysis. Conformational information of a protein must
be encoded into peptides beforehand. This encoding can be achieved
by labeling solvent-accessible amino acid side chains or backbones.
The labeling reagent can involve one reactive group that attaches
the reagent to various amino acids (protein footprinting), or have
two reactive groups that form a linkage between two amino acids
of a protein (protein crosslinking).
2.3.1. Protein footprinting
Footprinting examines ligand binding and conformational
changes by determining the solvent accessibility of macromole-
cules through their sensitive responses to chemical or enzymatic
modiﬁcation and cleavage reactions [50]. Protein footprinting as
a complementary approach to probing protein conformation has
rapidly developed during the last decade [51]. Footprinting strate-
gies are labeling approaches that include amide hydrogen deute-
rium exchange (HDX) and hydroxyl-radical based labeling; they
are becoming sufﬁciently characterized that they can have wide
usage. MS-based protein footprinting approaches can be classiﬁed
into two groups: reversible and irreversible, as is summarized in
Fig. 2B. Protein footprinting can also be combined with top-down
MS, as was shown recently [52,53].
In this review, we focus on the original bottom-up approach for
protein footprinting.
Reversible HDX footprinting. The hydrogens of solvent-accessible
amino-acid backbones and side chains can exchange with
deuterium when a protein in normal water is diluted into a buffer
containing D2O, initiating deuterium uptake by the amides and
other active sites of the protein. The mass shift induced by deute-
rium uptake can be monitored by MS to reveal some structural
features of a protein [54]. The resolution of the HDX MS platform
can be further improved by adding proteolytic digestion accom-
panied by LC separation [55]. At present, even super protein com-
plexes, like viral capsids and Escherichia coli ribosome, have been
analyzed by HDX MS [56,57], well beyond the capabilities of
NMR, which was the dominant tool in the early development of
HDX.
There are three types of hydrogens in proteins: those on side-
chain carbons, on heteroatoms, and on the backbone amide link-
ages. There is no measureable exchange for the carbon hydrogens,
whereas the exchange rate for most hydrogens on heteroatoms is
too fast to be followed during normal HDX LCMS experiments (ex-
cept for those on histidine [58]). Those on the backbone amides of
all amino acids (except proline) exchange at measurable rates. The
amide hydrogen exchange can be signiﬁcantly slowed (effectively
quenched) such that the rate constant decreases by 10000 times
when the conditions (pH 7 at 25 C) are changed (pH 2.5 at 0 C)
prior to MS analysis [59]. The quenching condition (pH 2.5) is com-
patible with denaturing positive-ion electrospray ionization (ESI),
making MS a good detector for the outcome of HDX. More impor-
tantly, mass shifts (induced by deuterium uptake) instead of peak
intensities are measured in MS based HDX, which avoids the prob-
lems of changes in ionization efﬁciency for the various constituent
peptides. Nevertheless, sample preparation and analysis of the
peptides to give ‘‘regional information’’ still must be done quickly
(e.g., <10 min), limiting chromatographic resolution and restricting
the use of complex matrices or samples for study.Irreversible footprinting approaches. For irreversible approaches,
the labeled protein sample can survive extensive separation and
puriﬁcation after the labeling experiment, whereas reversible
HDX suffers back exchange. The labeling approaches can be rela-
tively general or site-nonspeciﬁc [60] (e.g., hydroxyl radical label-
ing), or site-speciﬁc (such as carboxyl group labeling).
Hydroxyl radicals footprinting. Radicals are usually highly reac-
tive and have a short life time, making them good labeling reagents
in protein footprinting. The generation and control of radicals,
however, are not easy. Although development of other radical be-
sides OH as protein footprinting reagents have been reported
[53,61], the most popular radical in protein footprinting remains
the hydroxyl radical, which is similar in size as water molecules
and is highly reactive toward approximately two thirds of the ami-
no-acid side chains.
Hydroxyl radicals can be generated by electron-pulse radiolysis,
synchrotron radiolysis of water, laser photolysis of hydrogen per-
oxide, Fenton and Fenton-like reactions, and high-voltage electrical
discharges [62]. Although Fenton and Fenton-like reactions were
used early on for protein footprinting [63], the speed of Fenton
and Fenton-like reactions is relatively slow (minutes). To speed
up the process and avoid label-induced unfolding, synchrotron
radiolysis of water [64] and the laser photolysis of hydrogen perox-
ide to make radicals [65,66] are the most promising. The photolysis
of water in the kilovolt X-ray range causes water to ionize and lose
a proton to give hydroxyl radicals [67]. No reagent besides the sol-
vent water is required in this experiment. The reaction time can be
controlled by irradiation time. Chance’s group developed a system-
atic approach that uses a synchrotron light source, found in na-
tional labs, for protein footprinting studies [68]. Recently, that
group investigated the water distribution in the membrane-
embedded channel complexes [69]. The access to synchrotron light
sources, however, limits the general application of this method. La-
ser photolysis of hydrogen peroxide is an alternative that can be
set up in most chemistry laboratories.
We developed a laser photolysis approach, which we call Fast
Photochemical Oxidation of Protein (FPOP), to form OH, in a
few-nanosecond, 248 nm laser pulse that photolyzes low concen-
trations of hydrogen peroxide (0.04%, 15 mM) in a ﬂowing solution
containing the protein of interest. FPOP limits the radical lifetime
by using a scavenger (free amino acids, like glutamine or histidine)
to ensure the labeling reaction takes place within approximately
1 ls [70–72]. We took advantage of the fast labeling of FPOP to
study fast protein folding by a ‘‘pump-probe’’ method whereby
we use two lasers, one to supply a temperature jump, and the sec-
ond to generate hydroxyl radicals that footprint the protein as a
function of its folding time (hundreds of microsec) [73].
Glycl ethyl ester and other reagents label proteins in a site-speciﬁc
manner. A variety of chemical reagents can be used to modify spe-
ciﬁcally certain amino acids [23]; an example is the carbodiimide-
mediated coupling reaction between glycine ethyl ester and the
carboxyl groups of a protein [74]. Another example of a reactive
amino acid group is the thiol of cysteine, which can be modiﬁed
by several reagents (e.g., iodoacetamide, NEM [75]). Major draw-
backs of site-speciﬁc labeling are that the labeling is slow relative
to FPOP, and less conformational information can be obtained be-
cause the target residues on the surface are limited in number
(i.e., the method has limited structural resolution). Site-speciﬁc
labeling is recommended for studies of very complicated systems
that have hundreds of target residues. An advantage is the data
analysis, identifying and quantifying labeled products, can be sim-
pliﬁed because the target list can be narrowed. We reported sev-
eral examples that utilized site-speciﬁc labeling for the study of
complicated systems like membrane-embedded protein complexes
implicated in photosynthesis and cancer [76,77].
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The chemical-labeling attribute of protein footprinting can be
extended to chemical cross linking by using bi-functional labeling
reagents (e.g., N-hydroxysuccinimide esters). Chemical cross-link-
ers can modify two amino-acid side chains within a designed dis-
tance and form a covalent linker between the two residues,
provided the residues are with the distance constraint [24,78,79].
The cross-linked peptides can be identiﬁed by LC–MS/MS after pro-
teolytic digestion. Information about the distance between the two
residues, deﬁned by the length of cross-linker reagent, can be used
to determine adjoining proteins in a protein–protein interaction or
to locate within a protein two interacting domains. With the devel-
opment of new isotope-encoded linkers, cleavable linker, and
tagged linkers [80], protein crosslinking has become a more effec-
tive tool to determine sites of protein–protein interaction in com-
plicated biological systems.3. MS-based characterization of antibodies
The higher order structural variations of mAbs and their dynam-
ics must be addressed during discovery and development as thera-
peutics. Many approaches taken from structural biology can be
applied [16,19,20]. Traditional biophysical techniques, like X-ray
crystallography (X-ray), nuclear magnetic resonance (NMR) and
cryo-electron microscopy, are hampered by the size of the protein
and the need to determine dynamics of mAbs. MS has become an
essential analytical tool for the therapeutic mAb development ow-
ing to speed, allowing it to monitor primary structure and locate
post-translational modiﬁcations (PTMs) [6,81]. Variations of
primary structure, including those of disulﬁde-linkage location,
amino-acid sequence, PTM location, and other in-storage modiﬁca-
tions can be determined by MS in all phases of mAb production.
Although MS-based structural approaches are still limited by the
lower resolution compared to NMR and X-ray, they are more efﬁ-
cient because they have high sensitivity, can be applied to proteins
in complex environments, and have high throughput.
Applications by MS are rapidly growing [21,82]. Currently,
many MS-based biophysical approaches focus on differentiation
of mAb isomers [83,84]. Those isomers could arise as a conse-
quence of primary structural variations or variables in production
and storage. In this section, we review MS strategies that can ad-
dress three important and challenging issues: quality control of
high order structure (HOS), assessment of aggregation, and map-
ping of antibody-antigen interfaces. To provide future perspective,
we include several new developments in the MS-based biophysical
studies to demonstrate their potential for mAb characterization.3.1. Higher order structure (HOS)
3.1.1. Intact and top-down approaches
The observation of intact mAbs in native MS is the most direct
measurement of an antibody. We now can introduce mAbs into the
gas phase with minimal perturbation of their native conformation.
As a simple ﬁrst approach, we can follow the lead of Kaltashov
et al. [85], who reported that protein conformational variations
can be directly observed by observing their charge-state variations
when introduced to the mass spectrometer by native MS. This ap-
proach is recommended as an early one to apply for quality control
of mAb HOS [86].
Combining native MS and ion mobility provides a simple and
direct shape/size measurement of mAbs. Structural information
obtained from ion mobility refers to the global conformations of
species even with the same MW. The ﬁrst demonstration of ion
mobility for antibodies was by Bagal et al. [87] to differentiate,
using native ESI, the conformations of IgG2 isomers caused bydisulﬁde linkage variations. They used IgG1 as a control because
it does not have S–S isoforms, and found that IgG2 has a longer
drift time than IgG1 and shows two distinct peaks in the ATD
of each charge state. They concluded that these two peaks corre-
spond to IgG2-A (shorter time) and IgG2-B forms, respectively.
The double peaks were not caused by glycosylation, which was
conﬁrmed by redox-enrichment of A and B after refolding in
the presence and absence of GuHCl. Heck and coworkers [88]
used native MS to monitor the CH3 domain swapping between
human IgG4 molecules, a process related to spontaneous Fab-
arm exchange to form bi-speciﬁc antibodies [89]. Beck and
coworkers [90] monitored the dynamics of this process by using
native MS combined with time-resolved ion mobility; their re-
sults demonstrate the high potential of IM-MS for characterizing
biopharmaceutical protein products.
We in collaboration with colleagues at Pﬁzer [91] used a strat-
egy combining native ESI, ion mobility, ECD top-down, and hydro-
xyl-radical footprinting (FPOP) to characterize ﬁve IgG2 disulﬁde
isomers including the wild type. Ion mobility showed two major
drift time peaks for the WT isoform, consistent with Bagal’s obser-
vation [87]. The shorter drift time peak of the WT is approximately
the same as those of the other four mutants. ECD in a top-down
mode sequenced a ﬂexible portion of structure, providing a result
that is consistent with the FPOP results (Fig. 3).
3.1.2. Bottom-up approaches
At present, the most used bottom-up approach for characteriz-
ing mAb HOS is HDX. Most HDX studies differentiate mAb struc-
tural variations and provide evidence that the HOS of an
unknown protein is that of a reference (i.e., both give nearly iden-
tical HDX kinetics and extents (footprints) at the peptide level).
Differences in HDX pinpoint regions that have changed their
HOS. Summaries of protocols for HDX MS applications can be
found in recent publications [92,93]. Here, we describe several
examples that demonstrate how HDX MS provides HOS informa-
tion of mAbs.
Glycosylation changes antibody behavior, increases solubility,
imparts longer shelf-life, increases resistance to unfolding and pro-
teolysis, and lowers aggregation rates [94]. Little is known about
the relevant structural changes caused by glycosylation. Houde
et al. [95] utilized HDX MS to probe the conformational changes
for IgG1 with and without glycans. HDX MS can also be used to
probe structural variations and receptor binding induced by other
PTMs (e.g., methionine oxidation and fucosylation) [96,97]. One
major mAb isoform is a charge variant (or charge heterogeneity)
[98] designed to maintain optimized electrostatic interactions of
the favored structure and have the desired reactivity. Modiﬁcation,
degradation, and covalent adduction can result in net changes of
the positive or negative charge (pI value) of a mAb, and ultimately
change its structure and stability. Tang et al. [99] demonstrated
how HDX and an extended approach to give afﬁnity (i.e., SUPREX)
can characterize conformation and stability of charge variants of
human IgG1.
Variations of HOS may also result from storage of mAbs. Fur-
thermore, effects of excipients used in the therapeutic preparation
also need to be evaluated as to their effect on the stability of mAbs.
Manikwar et al. [100] reported the use of HDX MS to measure local
dynamics of mAbs stored in different environments. This approach
can be extended to examine the effects of salts on stability, aggre-
gation propensity, and local ﬂexibility of mAbs [101].
Hydroxyl-radical-based protein footprinting methods are a
more recent development than HDX, but they can also be applied
to protein therapeutics to afford information similar to that of
HDX. Watson et al. [102] demonstrated the use of FPOP in struc-
tural studies of the protein therapeutic, granulocyte colony-stimu-
lating factor (GCSF). Recently, we reported the application of FPOP
Fig. 3. Native ESI, IM and ECD mass spectra of WT IgG2, (A) ion mobility separation, (B) ECD top-down with in-source activation, and (C) highlighted region in yellow of light
chain in CDR showing ECD cleavage sites. (Copied with permission from JASMS).
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mAb IgG2 isomers. We found that the FPOP results are consistent
with top-down ECD data and point to ﬂexible regions of the pro-
tein. Furthermore, FPOP identiﬁes local conformational changes
and reveals solvent accessibility in the CDR [91]. Thus, FPOP com-
plements HDX but may be more reliable and versatile because it
imparts an irreversible change to the protein on the microsecond
timescale. Moreover, analysis of the outcome of free-radical foot-
printing can take advantage of advances in analytical proteomics.
Radical-labeling outcomes are a measure of solvent accessibility,
and the speed of FPOP can be used to locate dynamic or ﬂexible re-
gions of a protein. Other slower labeling approaches including HDX
give a time-averaged view.
Site-speciﬁc labeling can also measure solvent accessibility of
certain residues. Zhang et al. [103] applied the speciﬁc labeling
reagents, sulfosuccinimidyl acetate, for lysine and p-hydroxylphe-
nylglyoxal for arginine, to reveal a positive-charge patch on an
antibody. Free mAbs and a resin-bound antibody were labeled
and analyzed by LC-MS/MS. The charge distributions as well
as the antibody-resin binding interface were successfully
measured.
3.2. Protein aggregation
Antibody aggregation is a common problem occurring in pro-
tein manufacturing and storage [104]. The importance arises be-
cause the functional form of a protein is often the monomer,
whereas higher oligomers not only reduce the dose efﬁciency but
also pose toxicological problems. This is a serious issue facing the
biotechnology and pharmaceutical industries [105]. Understanding
the mechanism of aggregation is important, therefore, not only for
manufacturing and storage of proteins but also for shedding lighton protein aggregation in general. It is not surprising that protein
aggregation is attracting a considerable attention given that seri-
ous problems in human health can be caused by protein aggrega-
tion. The analytical tools used for analysis of protein aggregations
in neurodegenerative disease were recently reviewed [106], and
they may also be applicable to the problem of antibody
aggregation.
3.2.1. Intact and top-down approaches
Native ESI can be used to analyze monomeric antibodies and
their associated glycosylated forms. Given the narrower
charge-state distribution produced by native ESI, ion signals are
more concentrated than in normal ESI. Thus, the sensitivity for
the low-abundant modiﬁed forms becomes higher. The Heck
group in the Netherlands has observed IgG4 oligomers up to
tetramers by using this approach and even monitored the dynam-
ics of IgG4. When size-exclusion chromatography (SEC) is inte-
grated with native ESI, and combined with fractionation, the
antibody aggregates can be separated and analyzed in more detail
[107].
3.2.2. Bottom-up approaches for aggregation
Understanding the mechanism of aggregation and locating the
aggregation interface are vital to develop preventive measures.
We [108] developed a pulsed HD exchange labeling strategy that
can monitor the conformational changes during aggregation pro-
cesses of Abeta-42 peptide, adding a new approach to the ‘‘tool-
box’’ for protein aggregation studies. The approach should have
applicability for study of aggregation of other proteins, possibly
including antibodies. The advantages of this new platform are that
no modiﬁcation (e.g., addition of a ﬂuorophore) of the protein is
needed, information can be achieved at the peptide level, and
314 H. Zhang et al. / FEBS Letters 588 (2014) 308–317factors that affect aggregation can be readily evaluated for follow-
ing the HDX patterns.
Cross-linking can also be applied to proteins in different oligo-
meric states collected after SEC separation. Identiﬁcation of result-
ing linked peptides by bottom-up MS pinpoint the interface and
interaction regions.
Freeze–thaw stresses induce protein aggregation. Zhang et al.
[109] reported the use of MS-based HDX to assess the impact of
freeze–thaw cycling on protein structure, demonstrating that the
aggregation mechanism of mAbs under thermal and freeze–thaw
stresses can be revealed by HDX MS [110]. Engen’s group [111]
used H/DX and other biophysical measurements to compare the
monomeric and dimeric forms of two mAbs, respectively, to con-
nect aggregation with the structural changes in antibodies, They
found that the dimerization has no effect on the deuterium uptake
between monomer and dimer forms of one of the mAbs. However,
the other mAb monomer showed subtle changes in HDX in the CH
2 domain and the hinge region between CH 1 and CH 2 domains, as
compared with its dimer form.
Cold storage of proteins, particularly with traces of hydrogen
peroxide carried over from FPOP, for example, can lead to protein
oxidation [112]. Usually removal by various solid-phase desalting
methods, catalase treatment, or freeze-drying after protein foot-
printing is critical to insure no uncontrolled oxidation, which does
occur even at 80 C. Taking a positive view of this phenomenon,
we see possibilities to use cold chemical oxidation to bring insights
in a manner similar to FPOP or Fenton chemistry to protein aggre-
gation occurring in cold storage.
The combination of size-exclusion chromatography and hydro-
xyl radical labeling should be considered for the characterization of
mAb dimers [113]. The small amount of dimer in the mAb product
can be separated by SEC and labeled by hydroxyl radicals gener-
ated via synchrotron irradiation (ionization of water). The dimer
interface as well as the dimer orientation can be elucidated by this
footprinting and site-speciﬁc digestion[113].
Gu and coworkers [114] used cross-linking to probe the interac-
tion of the Fc moiety of a mAb expressed in Chinese hamster Ovary
cells. They formed aggregates by incubation at 40 C for 6 h, fol-
lowed by reaction with the bifunctional crosslinker BS3. Their re-
sults suggest the interaction occurs at three Fc molecules in theFig. 4. The MS based biophysical ‘‘tool box’’ in characterizations of IgG2 with different S-
to MS, to provide complementary structural information of mAbs. The experimental timCH2 and CH3 domains, indicating not only the Fab region but also
the Fc region can aggregate.
3.3. mAb complexes
3.3.1. Intact and top-down approaches
Antibody aggregates can be treated as homogeneous complexes
whereas antibody/antigen complexes are heterogeneous. Because
of the fast turnaround of native MS, it can be used to screen
small–molecules for drug candidates. For mixtures of small mole-
cules, the stoichiometry, relative intensity, and afﬁnity of mab/Ag
complexes can be obtained in one experiment. The relative inten-
sity should reﬂect the relative abundance of a complex, which can
be used for relative quantiﬁcation, assuming there is no discrimi-
nation in the native spray. Klassen and coworkers [115] have ex-
tended their program on protein/carbohydrate complexes to
assess antigen-binding fragments in an assay of carbohydrates.
Combining this approach with ECD top-down sequencing should
locate the binding pocket in such systems.
3.3.2. Bottom-up approaches
Antibody-antigen interactions are the core function of mAb
therapeutics. Understanding this interaction and locating the
interface (epitopes) are crucial in mAb design. Epitope mapping
is also involved in the patentability and protection of intellectual
property [93]. Footprinting by HDX and MS and comparing the
outcomes of free antigen and antibody-antigen complex can
locate the epitope binding region. A number of examples of this
approach were reported [109,116–119]. Similar approaches
should be possible with FPOP, and an example is illustrative,
underscoring the advantage of irreversible labeling for epitope
mapping [120]. One should be cautious in the interpretation of
epitope mapping data by FPOP or HDX. The changes induced by
antigen binding may be away from the epitope binding, resulting
from remote or allosteric effects [121], and these changes will
also be picked up. Furthermore, the binding imparts thermody-
namic stability to the protein that may cause overall protection.
Complementary information from other techniques, like model-
ing, site-directed mutagenesis, and X-ray [119], should help re-
solve these issues.S bond networks. This is an example of combining multiple approaches, not limited
e scale and structural resolution are labeled.
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Recently, mass spectrometry has seen a dramatic evolution in
instrumentation and method. In the meantime, the biotechnology
and pharmaceutical industries are in a stage of expansion that re-
quires new analytical means to characterize their protein products
at each step from preparation to storage and shipping. Mass spec-
trometry is poised to address higher order structure, aggregation,
and binding with antigens, providing a powerful physicochemical
approach that spins off its development for protein biophysics
and structural biology. MS information can serve as guideline for
production of the next generation of engineered therapeutic pro-
teins. No single method, however, can provide complete informa-
tion of a complex protein system. Rather, utilization of combined
methods (Fig. 4) including native MS, top-down and bottom-up
sequencing, footprinting, and modeling should be effective in gen-
erating a full picture of a protein.
For the future, the technological advances of mass spectrometry
will continue, driven in part by the complex problems in biological
sciences. For example, the recently modiﬁed Orbitrap Q-Exactive
instrument has demonstrated high sensitivity and resolving power
for large proteins and protein complexes [122] as demonstrated by
Heck and coworkers [123], who employed this instrument to
analyze intact antibodies. The implementation of ETD, SID, or UV
photodissociation [124] for MS/MS may provide a new dimension
of information for mAbs. UV photodissociation, owing to its fast
pulsing and high fragmentation efﬁciency, may drive top-down
sequencing to a new level. These combinations coupled with SEC
in the front end would increase the power of native ESI and top-
down MS/MS. Trapped ion mobility spectrometry (TIMS) [125]
has become a new member of the ion mobility family, showing
high resolution in just several centimeters drift length and suggest-
ing that improvement in IM are also forthcoming. All these new
developments would add to the collection of MS tools for the char-
acterization of protein therapeutics.
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